Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Tibotec Pharmaceuticals, Ireland Clear all
Completed Phase 3 Interventional

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

NCT00110877
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/rtv, TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
View directory record Official record
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

NCT00882908
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

NCT00071097
View directory record Official record
Conditions
HIV Infections
Interventions
TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

NCT01046058
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
TMC435
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
View directory record Official record
Conditions
HIV
Interventions
TMC125, Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

NCT00543725
View directory record Official record
Conditions
HIV Infections, HIV-1
Interventions
TMC278, efavirenz
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

NCT00540449
View directory record Official record
Conditions
HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
Interventions
TMC278, Efavirenz
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

NCT00258557
View directory record Official record
Conditions
HIV
Interventions
LPV/RTV, TMC-114/RTV
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

NCT00355524
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
TMC114, Ritonavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

NCT00980330
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Approved For Marketing No phase listed Expanded access

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

NCT00245739
View directory record Official record
Conditions
HIV Infections
Interventions
TMC-114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
202
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Approved For Marketing No phase listed Expanded access

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

NCT00354627
View directory record Official record
Conditions
HIV-1
Interventions
TMC125
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
182
States / cities
Anniston, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

NCT00359021
View directory record Official record
Conditions
HIV-1
Interventions
TMC125
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 6, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 6, 2026, 5:19 AM EDT